RBR-53r6n7招募中未知
Implant of the Inovare® Transfemoral Transcatheter ValveFeasibility and Verification of Safety and Efficacy Clinical Trial
Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da USP0 个研究点开始时间: 2020年2月17日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 90Y（—）
入选标准
- •Patients with significant calcified degenerative native aortic valve stenosis; Multidisciplinary evaluation by the Heart Team that concludes that the patient has a high surgical risk for aortic valve replacement or the presence of extreme fragility or the presence of comorbidities or aorta in porcelain or hostile chest; Symptoms of heart failure in NYHA functional class = II; Aortic valve ring with an average diameter between 17.3 and 28.6 mm, documented by imaging method, suitable for positioning and accommodating the Inovare® prosthesis; Coronary ostia height> 10 mm or presence of coronary graft that prevents the occurrence of acute myocardial ischemia due to coronary occlusion after the valve is released; Arterial femoral access route considered adequate for the progression of the vascular introducer and prosthesis-balloon system; Signed Free and Informed Consent Form.
排除标准
- •Clinicals: Hemodynamic instability with the need for vasoactive drugs or circulatory support; Valve procedure with clinical need to be performed in times of urgency or emergency (non-elective); Left ventricular ejection fraction <30%; Chronic dialysis renal failure; Acute renal failure with serum creatinine that has not yet returned to baseline levels; Clinical or biological signs of infection with systemic repercussions; Endocarditis <12 months; Coronary disease requiring elective revascularization during or after the valve procedure; Evidence of myocardial infarction in less than one month; Stroke or recent transient ischemic attack (in the last 6 months); Hypersensitivity or contraindication to the administration of heparin, ticlopidine or clopidogrel or to the radiopaque contrast medium; Anemia, thrombocytopenia or hyperthrombocytosis; Need for chronic anticoagulation for other causes; Active peptic disease, gastrointestinal bleeding <3 months or previously diagnosed hemorrhagic diasteses; Life expectancy less than 12 months due to non-heart disease or other comorbidities.
- •Anatomical / morphological: Valve ring diameter less than or equal to 17.2 mm or greater or equal to 28.7 mm; Iliac-femoral access route, with extreme tortuosity or calcification or reduced luminal diameter, which prevents the safe progression of the arterial introducer and delivery system with the prosthesis; Presence of sessile and unstable atheroma in the ascending aorta and / or aortic arch detected by imaging methods; Obstructive hypertrophic cardiomyopathy or severe obstruction of the left ventricular outflow tract, with no possibility of balloon dilation; Previous aortic or mitral valve procedure (surgical or by catheter, excluding balloon aortic valvuloplasty); Moderate or severe aortic, mitral or tricuspid insufficiency; Native valve not calcified; Evidence of intracardiac mass.
研究者
相似试验
招募中
不适用
Safety and efficacy of the Inovare® Transcatheter Valve Implantation via femoralAortic Valve StenosisRBR-744myhkInstituto do Coração do Hospital das Clínicas da Faculdade de Medicina da USP
进行中（未招募）
不适用
Transfemoral Implant of Inovare® Transcatheter ValveAortic Valve StenosisNCT05531578Braile Biomedica Ind. Com. e Repr. Ltda.60
进行中（未招募）
4 期
PMS plan is to provide local post marketing surveillance data regarding the safety of Medtronic CoreValveSystem FamilyCTRI/2016/05/006957India Medtronic Pvt Ltd
尚未招募
1 期
safety and efficacy of Haemodynamx device for aortic stenosisCTRI/2024/05/067405Translumina Therapeutics LLP
招募中
不适用
Trans-catheter aortic valve implantatioSevere aortic valve stenosisJPRN-UMIN000006880Osaka University Graduate School of medicine Department of Cardiovascular Surgery, Department of Cardiology53